Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease

Tatsuya Tagawa, Yoshitaka Hirooka, Hiroaki Shimokawa, Kiyoshi Hironaga, Koji Sakai, Jun Ichi Oyama, Akira Takeshita

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We have previously shown that long-term treatment with eicosapentaenoic acid (EPA) improves endothelium-dependent vasodilation of the atherosclerotic arteries in both animals and humans. The aim of the present study was to examine whether EPA treatment also improves metabolic vasodilation evoked by exercise in patients with coronary artery disease (CAD). Forearm blood flow (FBF) was measured by strain gauge plethysmography in 10 patients with stable CAD, before and 3 months after oral treatment with EPA (1,800 mg/kg). FBF was measured at rest and during intra-arterial infusion of acetylcholine or sodium nitroprusside, before and after intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA, an inhibitor of nitric oxide (NO) synthesis). A rhythmic handgrip exercise was also performed for 3 min before and after L-NMMA, and FBF was measured for 3 min just after the handgrip exercise. These protocols were repeated after the long-term treatment with EPA for 3 months. The long-term treatment with EPA significantly improved the FBF responses to acetylcholine (p<0.01), which was significantly reduced by acute administration of L-NMMA (p<0.01). By contrast, the EPA treatment did not affect the endothelium-independent responses to sodium nitroprusside. Metabolic increases in FBF caused by the handgrip exercise were not significantly decreased by L-NMMA before the EPA treatment. The EPA treatment significantly augmented the exercise-induced increases in FBF (p<0.05) and L-NMMA acutely abolished this augmentation (p<0.01). These results indicate that long-term treatment with EPA improves both endothelium-dependent and exercise-induced forearm vasodilations in patients with CAD and that NO is substantially involved in the EPA-induced improvement of the FBF responses in patients with CAD.

Original languageEnglish
Pages (from-to)823-829
Number of pages7
JournalHypertension Research
Volume25
Issue number6
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Eicosapentaenoic Acid
Vasodilation
Coronary Artery Disease
omega-N-Methylarginine
Forearm
Exercise
Endothelium
Therapeutics
Intra Arterial Infusions
Nitroprusside
Acetylcholine
Nitric Oxide
Plethysmography
Arteries

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Tagawa, T., Hirooka, Y., Shimokawa, H., Hironaga, K., Sakai, K., Oyama, J. I., & Takeshita, A. (2002). Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertension Research, 25(6), 823-829. https://doi.org/10.1291/hypres.25.823

Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. / Tagawa, Tatsuya; Hirooka, Yoshitaka; Shimokawa, Hiroaki; Hironaga, Kiyoshi; Sakai, Koji; Oyama, Jun Ichi; Takeshita, Akira.

In: Hypertension Research, Vol. 25, No. 6, 01.01.2002, p. 823-829.

Research output: Contribution to journalArticle

Tagawa, T, Hirooka, Y, Shimokawa, H, Hironaga, K, Sakai, K, Oyama, JI & Takeshita, A 2002, 'Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease', Hypertension Research, vol. 25, no. 6, pp. 823-829. https://doi.org/10.1291/hypres.25.823
Tagawa, Tatsuya ; Hirooka, Yoshitaka ; Shimokawa, Hiroaki ; Hironaga, Kiyoshi ; Sakai, Koji ; Oyama, Jun Ichi ; Takeshita, Akira. / Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. In: Hypertension Research. 2002 ; Vol. 25, No. 6. pp. 823-829.
@article{e2b1ae8ccbb047d89720b41f43cf25b9,
title = "Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease",
abstract = "We have previously shown that long-term treatment with eicosapentaenoic acid (EPA) improves endothelium-dependent vasodilation of the atherosclerotic arteries in both animals and humans. The aim of the present study was to examine whether EPA treatment also improves metabolic vasodilation evoked by exercise in patients with coronary artery disease (CAD). Forearm blood flow (FBF) was measured by strain gauge plethysmography in 10 patients with stable CAD, before and 3 months after oral treatment with EPA (1,800 mg/kg). FBF was measured at rest and during intra-arterial infusion of acetylcholine or sodium nitroprusside, before and after intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA, an inhibitor of nitric oxide (NO) synthesis). A rhythmic handgrip exercise was also performed for 3 min before and after L-NMMA, and FBF was measured for 3 min just after the handgrip exercise. These protocols were repeated after the long-term treatment with EPA for 3 months. The long-term treatment with EPA significantly improved the FBF responses to acetylcholine (p<0.01), which was significantly reduced by acute administration of L-NMMA (p<0.01). By contrast, the EPA treatment did not affect the endothelium-independent responses to sodium nitroprusside. Metabolic increases in FBF caused by the handgrip exercise were not significantly decreased by L-NMMA before the EPA treatment. The EPA treatment significantly augmented the exercise-induced increases in FBF (p<0.05) and L-NMMA acutely abolished this augmentation (p<0.01). These results indicate that long-term treatment with EPA improves both endothelium-dependent and exercise-induced forearm vasodilations in patients with CAD and that NO is substantially involved in the EPA-induced improvement of the FBF responses in patients with CAD.",
author = "Tatsuya Tagawa and Yoshitaka Hirooka and Hiroaki Shimokawa and Kiyoshi Hironaga and Koji Sakai and Oyama, {Jun Ichi} and Akira Takeshita",
year = "2002",
month = "1",
day = "1",
doi = "10.1291/hypres.25.823",
language = "English",
volume = "25",
pages = "823--829",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease

AU - Tagawa, Tatsuya

AU - Hirooka, Yoshitaka

AU - Shimokawa, Hiroaki

AU - Hironaga, Kiyoshi

AU - Sakai, Koji

AU - Oyama, Jun Ichi

AU - Takeshita, Akira

PY - 2002/1/1

Y1 - 2002/1/1

N2 - We have previously shown that long-term treatment with eicosapentaenoic acid (EPA) improves endothelium-dependent vasodilation of the atherosclerotic arteries in both animals and humans. The aim of the present study was to examine whether EPA treatment also improves metabolic vasodilation evoked by exercise in patients with coronary artery disease (CAD). Forearm blood flow (FBF) was measured by strain gauge plethysmography in 10 patients with stable CAD, before and 3 months after oral treatment with EPA (1,800 mg/kg). FBF was measured at rest and during intra-arterial infusion of acetylcholine or sodium nitroprusside, before and after intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA, an inhibitor of nitric oxide (NO) synthesis). A rhythmic handgrip exercise was also performed for 3 min before and after L-NMMA, and FBF was measured for 3 min just after the handgrip exercise. These protocols were repeated after the long-term treatment with EPA for 3 months. The long-term treatment with EPA significantly improved the FBF responses to acetylcholine (p<0.01), which was significantly reduced by acute administration of L-NMMA (p<0.01). By contrast, the EPA treatment did not affect the endothelium-independent responses to sodium nitroprusside. Metabolic increases in FBF caused by the handgrip exercise were not significantly decreased by L-NMMA before the EPA treatment. The EPA treatment significantly augmented the exercise-induced increases in FBF (p<0.05) and L-NMMA acutely abolished this augmentation (p<0.01). These results indicate that long-term treatment with EPA improves both endothelium-dependent and exercise-induced forearm vasodilations in patients with CAD and that NO is substantially involved in the EPA-induced improvement of the FBF responses in patients with CAD.

AB - We have previously shown that long-term treatment with eicosapentaenoic acid (EPA) improves endothelium-dependent vasodilation of the atherosclerotic arteries in both animals and humans. The aim of the present study was to examine whether EPA treatment also improves metabolic vasodilation evoked by exercise in patients with coronary artery disease (CAD). Forearm blood flow (FBF) was measured by strain gauge plethysmography in 10 patients with stable CAD, before and 3 months after oral treatment with EPA (1,800 mg/kg). FBF was measured at rest and during intra-arterial infusion of acetylcholine or sodium nitroprusside, before and after intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA, an inhibitor of nitric oxide (NO) synthesis). A rhythmic handgrip exercise was also performed for 3 min before and after L-NMMA, and FBF was measured for 3 min just after the handgrip exercise. These protocols were repeated after the long-term treatment with EPA for 3 months. The long-term treatment with EPA significantly improved the FBF responses to acetylcholine (p<0.01), which was significantly reduced by acute administration of L-NMMA (p<0.01). By contrast, the EPA treatment did not affect the endothelium-independent responses to sodium nitroprusside. Metabolic increases in FBF caused by the handgrip exercise were not significantly decreased by L-NMMA before the EPA treatment. The EPA treatment significantly augmented the exercise-induced increases in FBF (p<0.05) and L-NMMA acutely abolished this augmentation (p<0.01). These results indicate that long-term treatment with EPA improves both endothelium-dependent and exercise-induced forearm vasodilations in patients with CAD and that NO is substantially involved in the EPA-induced improvement of the FBF responses in patients with CAD.

UR - http://www.scopus.com/inward/record.url?scp=0036867246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036867246&partnerID=8YFLogxK

U2 - 10.1291/hypres.25.823

DO - 10.1291/hypres.25.823

M3 - Article

VL - 25

SP - 823

EP - 829

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 6

ER -